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Abstract Both cachexia and sarcopenia are associated with muscle wasting, although cachexia may also involve other tissues. Muscle wasting is encountered in the advanced stages of many chronic illnesses. Several ongoing pre-clinical and clinical studies are expected to ameliorate this clinical problem. This article highlights the pre-clinical and clinical studies in the field of wasting disorders that were presented at the 6th Cachexia Conference in Milan, Italy, in December 2011. Effective treatments are urgently needed in order to improve the patients' survival and quality of life. We describe ongoing research into muscle proteolytic pathways and the principal actors in skeletal muscle wasting. Novel therapeutic approaches include interleukin-6 such as receptor antibody tocilizumab, interleukin-1 receptor antagonist such as IP 1510 or selective androgen receptor modulators such as enobosarm and LGD-4033. Other candidates embraced the anabolic/catabolic transforming agent MT-102, naturally occurring peptide hormones such as ghrelin and synthetic orally active ghrelin receptor agonist anamorelin or the erythropoietin analogues ARA284 and ARA286.
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